文献速递心境障碍精神分裂症与精神病性障碍焦虑、强迫与应激相关障碍

安慰剂治疗中的负性效应:系统综述与Meta分析

Negative Effects During Placebo Treatment: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该研究比较9种主要精神障碍高质量随机对照试验安慰剂组的中途退出率,共纳入90项随机对照试验。结果发现安慰剂组总退出率在不同诊断间存在差异(Q=82.2,df=8,P<.001),精神分裂症和躁狂症退出率最高,注意缺陷多动障碍与重性抑郁障碍最低;因缺乏疗效退出最常见于精神分裂症和躁狂症,因不良事件退出最常见于强迫症和惊恐障碍。

要点

  • 安慰剂组总退出率在9种精神障碍诊断间存在显著差异(Q=82.2,df=8,P<.001)。
  • 精神分裂症安慰剂组总退出率最高(DR=0.41,95%CI 0.35-0.48),注意缺陷多动障碍与重性抑郁障碍最低(DR=0.17,95%CI 0.11-0.25)。
  • 因不良事件退出最常见于强迫症(DR=0.07,95%CI 0.05-0.09)和惊恐障碍研究。

核心结论

  • 安慰剂治疗与不良效应相关,且不同精神障碍诊断间存在差异。
  • 安慰剂的主要负性效应为缺乏疗效,诊断间差异与既往关于安慰剂阳性反应的分析结果一致。
  • 精神分裂症在安慰剂下病程最不利,重性抑郁障碍最有利。

研究设计与样本

  • 该分析属于一个更大型研究项目,采用系统方法为每种诊断识别最新的高质量系统综述(Open-Science-Foundation预注册:u469a)。
  • 从这些综述中为每种诊断选取10项最高质量且最新的安慰剂对照随机对照试验,共90项随机对照试验。
  • 检索与数据提取依据Cochrane手册进行,计算合并退出率(DR)及95%CI。

主要发现

  • 90项研究中有86项报告了总退出率,共10056名参与者。
  • 总退出率在诊断间存在差异(Q=82.2,df=8,P<.001),精神分裂症(DR=0.41,95%CI 0.35-0.48)、惊恐障碍和躁狂症最高,创伤后应激障碍、重性抑郁障碍和注意缺陷多动障碍最低(DR=0.17,95%CI 0.11-0.25)。
  • 因缺乏疗效退出率精神分裂症和躁狂症最高,注意缺陷多动障碍和重性抑郁障碍最低(Q=71.3,df=8,P<.001)。
  • 因不良事件退出率强迫症(DR=0.07,95%CI 0.05-0.09)和惊恐障碍研究最高,重性抑郁障碍和注意缺陷多动障碍试验最低(Q=32.1,df=8,P<.001)。
  • Meta回归未发现其他与退出率相关的因素。

关键数值与推荐

  • 主要结局为每种诊断的总退出率,采用随机效应Meta分析确定。
  • 诊断间差异采用Q检验进行统计学显著性检验。
  • 潜在混杂因素在多变量Meta回归分析中考察。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Analyzing effects within placebo groups allows for transdiagnostic comparisons, as placebo is the only substance systematically studied across all major psychiatric diagnoses. Recently, the study team meta-analytically showed that improvement under placebo varies across major psychiatric diagnoses. However, comprehensive transdiagnostic comparisons of negative effects under placebo (nocebo effects) are lacking. OBJECTIVE: To compare premature study termination rates in placebo groups of high-quality randomized clinical trials (RCTs) across 9 major psychiatric disorders, focusing on total dropouts, dropouts due to adverse events, and dropouts due to lack of effect. DATA SOURCES: This analysis is part of a broader research project using a systematic approach to identifying the most recent high-quality systematic review for each diagnosis (Open-Science-Foundation preregistered: u469a). STUDY SELECTION: From these reviews, the 10 highest quality and most recent placebo-controlled RCTs were selected for each diagnosis, totaling 90 RCTs. DATA EXTRACTION AND SYNTHESIS: Searches and data extraction were conducted according to the Cochrane Handbook. Pooled dropout rates (DRs) with 95% CIs were calculated. MAIN OUTCOMES AND MEASURES: The primary outcome was total DR per diagnosis, determined in random-effects meta-analyses. Diagnostic differences were tested for statistical significance using Q tests. Potential confounders were examined in multivariable meta-regression analyses. RESULTS: Eighty-six of the 90 studies reported total DRs (10 056 participants). DR differed between diagnoses (Q = 82.2; df = 8; P < .001), with schizophrenia (DR, 0.41; 95% CI, 0.35-0.48), panic disorder, and mania showing the highest rates, and posttraumatic stress disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) (DR, 0.17; 95% CI, 0.11-0.25) had the lowest. Schizophrenia and mania also had the highest DR due to lack of effect, while ADHD and MDD had the lowest (Q = 71.3; df = 8; P < .001). Most dropouts due to adverse events occurred in obsessive-compulsive disorder (DR, 0.07; 95% CI, 0.05-0.09) and panic disorder studies and the fewest occurred in MDD and ADHD trials (Q = 32.1; df = 8; P < .001). Meta-regression revealed no additional associated factors on DRs. CONCLUSION AND RELEVANCE: These findings indicate that placebo treatment is associated with adverse effects that differ among psychiatric diagnoses. The main negative effect was lack of effect, with diagnostic variations corroborating findings on positive placebo response from earlier analyses. Schizophrenia had the least favorable course under placebo, while MDD demonstrated the most favorable.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bschor T, Unger J, Nagel L, et al. Negative Effects During Placebo Treatment: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40238101. doi:10.1001/jamapsychiatry.2025.0336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。